The NHS has broadened who can receive Mounjaro on prescription, with new rules now covering patients with a BMI of 35 or above alongside qualifying health conditions. This change is already embedded in GP contracts across England. Here is exactly what has changed and whether you might now qualify.
The NHS Mounjaro rollout has entered a significant new phase in England, expanding access to tirzepatide — the active ingredient in Mounjaro — to a broader group of patients. This development was announced on June 2026.
According to NHS England and GOV.UK, patients with a BMI of 35 or above who also have at least four qualifying weight-related health conditions may now be eligible for tirzepatide on the NHS. This is a meaningful shift from the earlier, more restricted criteria that left many people unable to access the drug through their GP.
The change is not just a policy announcement. According to NHS England, tirzepatide prescribing is now written into the 2026/27 GP contract through new Quality and Outcomes Framework (QOF) indicators, which came into force on 1 April 2026. QOF is the system that sets targets for GP practices and links them to funding. In plain English: GPs now have a formal, funded reason to prescribe Mounjaro — not just permission to do so.
What Has Actually Changed?
Until now, NHS access to Mounjaro was tightly controlled and often limited to specialist weight management services. Many GPs either could not prescribe it or chose not to because it sat outside their normal contract. According to NHS England, embedding tirzepatide into the QOF framework changes that dynamic directly at GP level.
The new eligibility threshold focuses on a BMI of 35 or above, combined with four qualifying conditions. According to NHS England, these conditions are weight-related health problems such as high blood pressure, type 2 diabetes, sleep apnoea, or cardiovascular disease — though the full approved list sits within NHS clinical guidance. Patients who meet the criteria should now be able to raise this with their GP directly, rather than waiting for a specialist referral.
This matters because the previous bottleneck was not just about who qualified on paper. It was about whether a GP had the framework to act. That barrier has now been formally removed for practices following the 2026/27 contract.
Why Mounjaro? A Quick Reminder
Tirzepatide works by targeting two hormones — GLP-1 and GIP — that regulate hunger and blood sugar. According to NICE, clinical trials showed Mounjaro helped patients lose an average of around 20 percent of their body weight over 72 weeks. That is a significantly larger result than earlier GLP-1 drugs such as semaglutide (the active ingredient in Ozempic and Wegovy) produced in comparable studies.
For patients who have tried other weight loss treatments without lasting success, tirzepatide now represents the most effective option available on NHS prescription in England. If you are new to this area, our Weight Loss Jabs Guide explains how these treatments work in plain English.
What This Means For UK Patients
This is the most practically significant NHS access change to weight loss treatment in years. But expanded eligibility on paper does not automatically mean your GP surgery will act quickly. Practices are still adapting to the new QOF indicators, and some may be slower than others to proactively offer this to qualifying patients. If you have a BMI of 35 or above and manage four or more weight-related health conditions, do not wait to be invited. Book a GP appointment and ask specifically whether you now qualify for tirzepatide under the 2026/27 NHS contract. Go prepared with your list of conditions. If your practice is uncertain or says it cannot help, you have every right to ask for a referral to a specialist weight management service. Private clinics remain an option for those who do not qualify or cannot wait, but with NHS access genuinely widening, it is worth trying the NHS route first. You can find trusted private options in our UK Clinic Reviews section if needed.
Frequently Asked Questions
What BMI do I need to get Mounjaro on the NHS?
According to NHS England, the updated criteria require a BMI of 35 or above, alongside at least four qualifying weight-related health conditions. This new threshold came into effect as part of the 2026/27 GP contract from April 2026.
Will my GP automatically offer me Mounjaro now?
Not necessarily. According to NHS England, tirzepatide is now embedded in the QOF framework, which gives GPs a funded mechanism to prescribe it. However, practices are at different stages of implementation, so you may need to ask directly at your next appointment.
What are the qualifying conditions for NHS Mounjaro eligibility?
According to NHS England, qualifying conditions are weight-related health problems including type 2 diabetes, high blood pressure, cardiovascular disease, and sleep apnoea, among others. Your GP will assess which conditions count based on current NHS clinical guidance.
Can I get Mounjaro privately if I do not qualify on the NHS?
Yes. According to the MHRA, Mounjaro is licensed in the UK for weight management in adults with a qualifying BMI, and private clinics can prescribe it independently of NHS criteria. Our Start Here guide explains how to approach both NHS and private routes safely.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment.
Get the UK peptide medicine briefing in your inbox.
Free weekly. No spam. Unsubscribe any time.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any treatment. Information correct at time of publication. The Peptide Brief updates articles when guidance changes.
